Ayuryoga, Inc.
FDA issued a warning letter to Ayuryoga, Inc. (New Paltz, NY, United States) on May 19, 2022. Subject: Unapproved New Drug.
From the letter: “The claims on your website and social media websites establish that your Kottakkal ayurvedic products are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C.”
At a glance
What a reviewer notes before reading: findings, citations, the response deadline and what the letter warns of.
- Violations
- 2 findings · 1 issue type
- Cited
- No CFR or ISO section
- Response due
- 15 working days after receipt of this letter
- FDA asks for
- 3 actions
- Named as possible actions
- Seizure, injunction
- Issued by
- Center for Drug Evaluation and Research
- Published status
- No close-out recorded
AI assisted findings
Model-assisted reading of each issue. Open one to see the FDA text it comes from, and check it against the full letter.
01Labeling, claims & marketingAyurvedic products were marketed with disease claims, making them unapproved new drugs.
The claims on your website and social media websites establish that your Kottakkal ayurvedic products are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C.
02Labeling, claims & marketingProducts are new drugs without FDA approval because they are not generally recognized as safe and effective.
Your Kottakkal ayurvedic products are also “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in their labeling.
What FDA requested
- Notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps taken to address any violations, including an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation.
- If corrective actions cannot be completed within 15 working days, state the reason for the delay and the time within which you will do so.
- If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.
FDA Warning Letter
75 paragraphs · 16 sectionsText as published on FDA.gov, retrieved Oct 14, 2026. Layout added for reading; the wording is FDA’s. View on FDA.gov (opens in a new tab)
Nikhil Gupta Ayuryoga, Inc., d/b/a Kottakkal Ayurveda USA 332 Springtown Road New Paltz, NY 12561 Contact@ayuryoga.com
RE: 628168
1Introduction
1 paragraph
This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https://www.kottakkalusa.com/, which redirects to https://www.kottakkal.shop/, in March 2022 and has observed that you take orders there for various ayurvedic products, including but not limited to “Arjuna Arishtam,” “Ashtavargam Kwatham,” “Ashwagandha Arishtam,” “Draksha Arishtam,” “Dasamulaharitaki Leham,” “Amritamehari Churnam,” “Ashoka Arishtam,” “Brahmi Caps,” “Chandraprabha Vatika,” “Dadimashtaka Churnam,” “Dhanwantaram (101) Softgel Capsule,” “Kshirabala Oil,” and “Lohasinduram (7) Capsules” (hereinafter referred to as your “Kottakkal ayurvedic products”). We have also reviewed your Facebook, Instagram, LinkedIn, and Twitter social media websites at the Internet addresses https://www.facebook.com/kottakkalayurvedausa, https://www.instagram.com/kottakkalayurvedausa/, https://www.linkedin.com/company/kottakkalayurvedausa and https://twitter.com/Kottakkal_USA, respectively; these social media websites direct consumers to your website at https://www.kottakkal.shop/ to purchase your products. The claims on your website and social media websites establish that your Kottakkal ayurvedic products are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov.
2Unapproved New Drugs
1 paragraph
Based on a review of your websites, your Kottakkal ayurvedic products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or function of the body. Examples of claims observed on your website and social media websites that establish the intended use of your Kottakkal ayurvedic products as drugs include, but may not be limited to, the following:
3Arjuna Arishtam
4 paragraphs
On the product webpage for “Arjuna Arishtam,” https://www.kottakkal.shop/products/arjuna-arishtam:
• “Arjuna Arishtam is a liquid . . . used to support the healing of diabetes, leucoderma and skin disorders. . . . improves heart function and reduces high blood pressure.” • “Indications[:] Chronic fatigue[.] Chronic respiratory problems[.] Mild to moderate hypertension[.] Anemia[.] Throat related diseases[.] Cardiac disorders[.] Heart diseases[.]”
On the blog post titled, “Managing High Blood Pressure with Ayurveda,”1 https://www.kottakkal.shop/blogs/healing-with-kottakkal-ayurveda/managing-high-blood-pressure-with-ayurveda?fbclid=IwAR1usiUno4Y09aw5B9u0uk%E2%80%A6:
• “Ayurveda has solutions for managing high blood pressure. . . . THREE PRODUCTS TO HELP HIGH BLOOD PRESSURE . . . Arjuna Arishtam supports healthy heart function and reduces high blood pressure.”
4Ashtavargam Kwatham
2 paragraphs
On the product webpage for “Ashtavargam Kwatham,” https://www.kottakkal.shop/products/ashtavargam-kwatham:
• “Ashtavargam Kwatham. . . relieving joint stiffness” • “Indications[:] . . . Numbness[.] Arthritis[.] Rheumatism[.] Paralysis of different etiology[.] Ischemic disorders[.]”
5Ashwagandha Arishtam
2 paragraphs
On the product webpage for “Ashwagandha Arishtam,” https://www.kottakkal.shop/products/ashwagandha-arishtam:
• “Ashwagandha Arishtam . . . heal sexual disorders, relieve depression . . . This arishtam and remedies premature ejaculation and erectile dysfunction” • “Indications[:] . . . Arthritis[.] Epilepsy[.] Emaciation[.] Hemorrhoids. Neurological disorders[.] Recurring fainting or episodes of unconsciousness[.]”
6Draksha Arishtam
2 paragraphs
On the product webpage for “Draksha Arishtam,” https://www.kottakkal.shop/products/draksha-arishtam:
• “Draksha Arishtam . . . heals respiratory diseases. . . . relieves symptoms of gastritis and hyperacidity. . . . cure skin diseases resulting from a Pitta Dosha imbalance.” • “Indications[:] Colds[.] Coughs[.] Constipation[.] Asthma[.] Throat infections. Chest injuries[.] Tuberculosis[.] Chronic Obstructive Pulmonary Disease (COPD)[.]”
7Dasamulaharitaki Leham
4 paragraphs
On the product webpage for “Dasamulaharitaki Leham,” https://www.kottakkal.shop/products/dasamulaharitaki-leham:
• “Dasamulaharitaki Leham . . . support the treatment of respiratory ailments and urinary bladder disorders. . . . used to remedy chronic inflammatory conditions, fevers, emaciation, rheumatoid arthritis, bleeding diseases and liver diseases” • “Indications[:] Generalized edema[.] Genito-urinary diseases[.] Splenomegaly[.] Ascitis[.] Hypertension[.]”
On a July 13, 2016, post from your Facebook social media website, https://www.facebook.com/kottakkalayurvedausa:
• “Dasamulaharitaki Leham is an Ayurvedic herbal jam used to support the treatment of respiratory ailments, debilitating diseases, urinary bladder disorders, hoarseness of voice, bleeding diseases, urinary infections, gulma, anemia and liver diseases. It is rich in nutrition and clears the bowels.” • “Dose: 2 – 10 grams once or twice a day, or as directed by an Ayurvedic doctor.”
8Amritamehari Churnam
6 paragraphs
On the product webpage for “Amritamehari Churnam,” https://www.kottakkal.shop/products/amritamehari-churnam:
• “Amritamehari Churnam . . . powerful herb reduces high blood sugar levels” • “Indications[:] Diabetes[.]”
On the webpage titled, “Balancing High Blood Sugar with Ayurveda,” 2 https://www.kottakkal.shop/blogs/healing-with-kottakkal-ayurveda/balancing-high-blood-sugar-with-ayurveda:
• “Amritamehari Churnam . . . for people suffering with high blood sugar. . . actions are antidiabetic and antihyperglycemic . . . normalize the blood glucose level. . . stimulates the pancreas to release more insulin.”
On a July 13, 2016, post from your Facebook social media website https://www.facebook.com/kottakkalayurvedausa:
• “Amritamehari Churnam is an Ayurvedic herbal powder used to heal Diabetes mellitus and relieve its symptoms. This powerful herb reduces high blood sugar levels”
9Ashoka Arishtam
4 paragraphs
On the product webpage for “Ashoka Arishtam,” https://www.kottakkal.shop/products/ashoka-arishtam:
• “Ashoka Arishtam . . . used to heal menorrhagia, fevers and bleeding hemorrhoids. Ashoka Arishtam acts as well as a hemostatic.” • “Indications[:] Fever[.]. . . Heavy menstrual bleeding[.] Dysmenorrhoea (painful periods)[.] Anorexia[.] Bleeding hemorrhoids[.]”
On an April 3, 2014, post from your Facebook social media website3 https://www.facebook.com/kottakkalayurvedausa:
• “Ashoka Arishtam is a liquid Ayurvedic remedy used to heal menorrhagia, fevers, bleeding hemorrhoids and more. It acts as a as well as a hemostatic.”
10Brahmi Caps
2 paragraphs
On the product webpage for “Brahimi Caps,” https://www.kottakkal.shop/products/brahmi-caps:
• “Brahmi Capsules are used to help relieve insomnia, increase memory retention and improve concentration. . . . well-known for its ability to reverse the aging process. It is also has [sic] powerful antidiabetic, antioxidant and antiaging properties.” • “Indications[:] Dementia[.] Seizure disorders[.] Learning disabilities[.]”
11Chandraprabha Vatika
4 paragraphs
On the product webpage for “Chandraprabha Vatika,” https://www.kottakkal.shop/products/chandraprabha-vatika:
• “Chandraprabha Vatika . . . acts as an aphrodisiac, antimicrobial and antiaging remedy. . . . relieving constipation, eczema and eye infections.” • “Indications[:] Constipation[.] Eczema[.] Urinary tract infections[.] Respiratory diseases[.] Difficulty urinating[.] Urinary calculi[.] Dermatitis[.] Liver and spleen diseases[.]”
On the webpage titled, “Ayurvedic Guidance for Polycystic Ovarian Syndrome,”4 https://www.kottakkal.shop/blogs/healing-with-kottakkal-ayurveda/ayurvedic-guidance-for-polycystic-ovarian-syndrome:
• “Chandraprabha Vatika: is a tonic for the reproductive system and acts as a muscle relaxant due its [sic] anti-spasmodic action. It can help correct hormonal imbalance and helps regulate the menstrual cycle. Chandraprabha Vati is especially helpful when used in combination with Ashoka Arishtam.”
12Dadimashtaka Churnam
2 paragraphs
On the product webpage for “Dadimashtaka Churnam,” https://www.kottakkal.shop/products/dadimashtaka-churnam:
• “Dadimashtaka Churnam. . . used to cure malabsorption disorders and amoebic dysentery. . . . used to relieve symptoms of indigestion, malabsorption syndrome and diarrhea. Dadimashtaka is also useful in healing respiratory conditions like a chronic cough.” • “Indications[:] Irritable Bowel Syndrome (IBS) [.] Malabsorption disorders[.] Amoebic dysentery[.]”
13Dhanwantaram (101) Softgel Capsule
4 paragraphs
On the product webpage for “Dhanwantaram (101) Softgel Capsule,” https://www.kottakkal.shop/products/dhanwantaram-101-softgel-capsule:
• “Useful for. . . conditions of arthritis, paralysis, skeletal and neuromuscular conditions. Promotes, healthy postpartum care for mothers.” • “Indications[:] Arthritis[.] Paralysis[.] Skeletal diseases[.] Neuromuscular diseases[.]”
On a November 11, 2021, post from your Instagram social media website https://www.instagram.com/kottakkalayurvedausa/:
• “#Dhanwantaram . . . highly effective for breathlessness, severe cough, chronic hiccups, giddiness, nausea, antenatal and postpartum care, neurological pain and fatigue.”
14Kshirabala Oil
5 paragraphs
On the product webpage for “Kshirabala Oil,” https://www.kottakkal.shop/products/kshirabala-oil:
• “Kshirabala Oil . . . support the treatment of Vata disorders causing neuromuscular pains, sciatica, spondylosis and paralysis. This herbal oil helps to relieve inflammation and pain. It is used in sciatica, osteoarthritis, myalgia and spondylosis, among many other health issues.” • “Indications[:] Arthritis[.] Spondylosis[.] Sciatica[.] Myalgia[.] Neuralgia[.]”
On the webpage titled, “Nourishing Muscles, Joints and Nerves for Strength,”5 https://www.kottakkal.shop/blogs/healing-with-kottakkal-ayurveda/nourishing-muscles-joints-and-nerves-for-strength?fbclid=IwAR2wn1_oYywAGUn2w%E2%80%A6:
• “One of the best oils for daily Abhyanga is Kshirabala Oil. . . . made from three highly nourishing ingredients: sesame oil, cow’s milk, and an herb called bala (Sida cordifolia). . . . support damaged bones, muscles, joints, ligaments, tendons and nerves. . . . bala (Sida cordifolia), is a powerful neuroprotective herb. . . .well-known for its nerve rejuvenating properties and alleviating pain caused by irritated nerves. . . .Kshirabala Oil is neuroprotective, nerve tonic, antioxidant, anti-inflammatory, and anti-arthritic.”
• “Kshirabala oil relieves the following health conditions: Body and facial paralysis • Hemiplegia caused by stroke • Sciatica nerve pain • Vata gynecological disorders . . . • Herpes and shingles nerve pain • Hypospermia (low ejaculate) • Insomnia • Osteoarthritis or Osteoporosis bone pain . . . • Myalgia or muscle pain • Minor vision impairment • Degenerative neurological disorders”
15Lohasinduram (7) Capsules
3 paragraphs
On the product webpage for “Lohasinduram (7) Capsules,” https://www.kottakkal.shop/products/lohasinduram-7-capsule:
• “Lohasinduram 7 Capsules are used for the Ayurvedic treatment of anemia, splenomegaly, helminthiasis, vomiting and asthma. . . . useful in Ayurvedically treating cardiovascular diseases as well as improving physical strength, immunity, memory and digestion. It is a powerful aphrodisiac as well as a blood purifier.” • “Indications[:] Asthma[.] Chronic respiratory problems[.] Anemia[.] Splenomegaly[.] Helminthiasis[.] Vomiting[.]”
Your Kottakkal ayurvedic products are also “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.
16Conclusion
3 paragraphs
This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. While FDA has mentioned specific Kottakkal ayurvedic products in this letter, there are drug claims being made on your website and social media websites for a wide range of your products. As such, the cited violations in this letter should not be viewed to apply solely to the specific products mentioned in this letter. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.
This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction. Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.
Your response should refer to unique identifier CMS 628168 and be sent to U.S. Food and Drug Administration, CDER/OC/Office of Unapproved Drugs and Labeling Compliance, by email to FDAADVISORY@fda.hhs.gov.
Citations and trends
Each 21 CFR section, ISO 13485 clause and issue type in this letter, how often it appears across all letters, and its trend by the year FDA issued the letters. 2026 runs to Nov 3, 2026, compared with the same dates last year. Select a row or a bar to see those letters in Letters. As cited in this historical letter, not a statement of current requirements.
This letter cites no 21 CFR section or ISO 13485 clause.
Issue types
Record details
- Issuing center
- Center for Drug Evaluation and Research
- Issuing office
- Center for Drug Evaluation and Research
- Location
- New Paltz, NY, United States
- Letter posted date
- May 24, 2022
- Letter issue date
- May 19, 2022
- Addressed to
- Not recorded
- Inspection dates · model-assisted
- Mar 1, 2022 to Mar 31, 2022
- Response window
- 15 working days after receipt of this letter
Read the source clause
Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations.
- Record length
- 2,213 words · 0 recorded redactions
- Published status
- No published close-out
- FDA reference
- 628168
- Original letter
- View on FDA.gov (opens in a new tab)
- Dataset last checked
- Nov 11, 2026 · How this is built
A response window is not a calculated due date. Source excerpts are selected passages. Finding interpretations and categories are model-assisted. Verify the original letter before relying on a finding.